Form 8-K - Current report:
SEC Accession No. 0001104659-24-128212
Filing Date
2024-12-13
Accepted
2024-12-13 06:43:14
Documents
15
Period of Report
2024-12-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2430949d1_8k.htm   iXBRL 8-K 33897
2 EXHIBIT 10.1 tm2430949d1_ex10-1.htm EX-10.1 949665
3 EXHIBIT 99.1 tm2430949d1_ex99-1.htm EX-99.1 12211
  Complete submission text file 0001104659-24-128212.txt   1375733

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA espr-20241212.xsd EX-101.SCH 3015
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE espr-20241212_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE espr-20241212_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2430949d1_8k_htm.xml XML 3697
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35986 | Film No.: 241546747
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)